Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 1997 Jul 1; 100(1): 127–135.
PMCID: PMC508172

Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease.


The recently described anti-A2/RA33 autoantibodies occur in 20-40% of patients with RA, SLE, and mixed connective tissue disease (MCTD). They are directed to the A2 protein of the heterogeneous nuclear ribonucleoprotein complex (hnRNP-A2), an abundant nuclear protein associated with the spliceosome. The NH2-terminal half of the antigen contains two conserved RNA binding domains whereas its COOH-terminal part is extremely glycine-rich. The aim of this study was to characterize the autoepitopes of hnRNP-A2 and to investigate the effects of anti-A2/RA33 autoantibodies on possible functions of the antigen. Using bacterially expressed fragments, two major discontinuous epitopes were identified. One containing the complete second RNA binding domain was recognized by the majority of patients with RA and SLE but not by patients with MCTD. The second epitope contained sequences of both RNA binding domains and was preferentially targeted by patients with MCTD. When the RNA binding properties of the antigen were investigated, oligoribonucleotides containing the sequence motif r(UUAG) were found to bind to a site closely adjacent or overlapping with the epitope targeted by autoantibodies from patients with RA and SLE. Moreover, anti-A2/RA33 autoantibodies from patients with RA or SLE, but not from patients with MCTD, inhibited binding of RNA. Thus, anti-A2/RA33 autoantibodies recognize conformation-dependent epitopes located in a functionally important region of the antigen. Furthermore, the specific recognition of an epitope by MCTD patients may be used as another argument in favor of considering MCTD a distinct connective tissue disease.

Full Text

The Full Text of this article is available as a PDF (341K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum. 1995 Apr;24(5):323–358. [PubMed]
  • van Venrooij WJ, Pruijn GJ. Ribonucleoprotein complexes as autoantigens. Curr Opin Immunol. 1995 Dec;7(6):819–824. [PubMed]
  • Hassfeld W, Steiner G, Hartmuth K, Kolarz G, Scherak O, Graninger W, Thumb N, Smolen JS. Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum. 1989 Dec;32(12):1515–1520. [PubMed]
  • Hassfeld W, Steiner G, Graninger W, Witzmann G, Schweitzer H, Smolen JS. Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br J Rheumatol. 1993 Mar;32(3):199–203. [PubMed]
  • Youinou P, Serre G. The antiperinuclear factor and antikeratin antibody systems. Int Arch Allergy Immunol. 1995 Aug;107(4):508–518. [PubMed]
  • Sebbag M, Simon M, Vincent C, Masson-Bessière C, Girbal E, Durieux JJ, Serre G. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1995 Jun;95(6):2672–2679. [PMC free article] [PubMed]
  • Després N, Boire G, Lopez-Longo FJ, Ménard HA. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol. 1994 Jun;21(6):1027–1033. [PubMed]
  • Steiner G, Hartmuth K, Skriner K, Maurer-Fogy I, Sinski A, Thalmann E, Hassfeld W, Barta A, Smolen JS. Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. J Clin Invest. 1992 Sep;90(3):1061–1066. [PMC free article] [PubMed]
  • Dreyfuss G, Matunis MJ, Piñol-Roma S, Burd CG. hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem. 1993;62:289–321. [PubMed]
  • Simon MM, Prester M, Kramer MD, Fruth U. An inhibitor specific for the mouse T-cell associated serine proteinase 1 (TSP-1) inhibits the cytolytic potential of cytoplasmic granules but not of intact cytolytic T cells. J Cell Biochem. 1989 May;40(1):1–13. [PubMed]
  • Hassfeld W, Steiner G, Studnicka-Benke A, Skriner K, Graninger W, Fischer I, Smolen JS. Autoimmune response to the spliceosome. An immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. Arthritis Rheum. 1995 Jun;38(6):777–785. [PubMed]
  • Meyer O, Tauxe F, Fabregas D, Gabay C, Goycochea M, Haim T, Elias A, Kahn MF. Anti-RA 33 antinuclear autoantibody in rheumatoid arthritis and mixed connective tissue disease: comparison with antikeratin and antiperinuclear antibodies. Clin Exp Rheumatol. 1993 Sep-Oct;11(5):473–478. [PubMed]
  • Piñol-Roma S, Choi YD, Matunis MJ, Dreyfuss G. Immunopurification of heterogeneous nuclear ribonucleoprotein particles reveals an assortment of RNA-binding proteins. Genes Dev. 1988 Feb;2(2):215–227. [PubMed]
  • Piñol-Roma S, Dreyfuss G. Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm. Nature. 1992 Feb 20;355(6362):730–732. [PubMed]
  • Mayeda A, Munroe SH, Cáceres JF, Krainer AR. Function of conserved domains of hnRNP A1 and other hnRNP A/B proteins. EMBO J. 1994 Nov 15;13(22):5483–5495. [PMC free article] [PubMed]
  • Burd CG, Swanson MS, Görlach M, Dreyfuss G. Primary structures of the heterogeneous nuclear ribonucleoprotein A2, B1, and C2 proteins: a diversity of RNA binding proteins is generated by small peptide inserts. Proc Natl Acad Sci U S A. 1989 Dec;86(24):9788–9792. [PMC free article] [PubMed]
  • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. [PubMed]
  • Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. [PubMed]
  • Strebel K, Beck E, Strohmaier K, Schaller H. Characterization of foot-and-mouth disease virus gene products with antisera against bacterially synthesized fusion proteins. J Virol. 1986 Mar;57(3):983–991. [PMC free article] [PubMed]
  • McKay SJ, Cooke H. hnRNP A2/B1 binds specifically to single stranded vertebrate telomeric repeat TTAGGGn. Nucleic Acids Res. 1992 Dec 25;20(24):6461–6464. [PMC free article] [PubMed]
  • Ishikawa F, Matunis MJ, Dreyfuss G, Cech TR. Nuclear proteins that bind the pre-mRNA 3' splice site sequence r(UUAG/G) and the human telomeric DNA sequence d(TTAGGG)n. Mol Cell Biol. 1993 Jul;13(7):4301–4310. [PMC free article] [PubMed]
  • Burd CG, Dreyfuss G. RNA binding specificity of hnRNP A1: significance of hnRNP A1 high-affinity binding sites in pre-mRNA splicing. EMBO J. 1994 Mar 1;13(5):1197–1204. [PMC free article] [PubMed]
  • Aho K, Steiner G, Kurki P, Paimela L, Leirisalo-Repo M, Palosuo T, Smolen JS. Anti-RA 33 as a marker antibody of rheumatoid arthritis in a Finnish population. Clin Exp Rheumatol. 1993 Nov-Dec;11(6):645–647. [PubMed]
  • Barakat S, Briand JP, Abuaf N, van Regenmortel MH, Muller S. Mapping of epitopes on U1 snRNP polypeptide A with synthetic peptides and autoimmune sera. Clin Exp Immunol. 1991 Oct;86(1):71–78. [PMC free article] [PubMed]
  • Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972 Feb;52(2):148–159. [PubMed]
  • McHugh N, James I, Maddison P. Clinical significance of antibodies to a 68 kDa U1RNP polypeptide in connective tissue disease. J Rheumatol. 1990 Oct;17(10):1320–1328. [PubMed]
  • Kallenberg CG. Overlapping syndromes, undifferentiated connective tissue disease, and other fibrosing conditions. Curr Opin Rheumatol. 1995 Nov;7(6):568–573. [PubMed]
  • Citera G, Lázaro MA, Maldonado Cocco JA. Mixed connective tissue disease: fact or fiction? Lupus. 1995 Aug;4(4):255–257. [PubMed]
  • Steiner G, Skriner K, Smolen JS. Autoantibodies to the A/B proteins of the heterogeneous nuclear ribonucleoprotein complex: novel tools for the diagnosis of rheumatic diseases. Int Arch Allergy Immunol. 1996 Dec;111(4):314–319. [PubMed]
  • Montecucco C, Caporali R, Negri C, de Gennaro F, Cerino A, Bestagno M, Cobianchi F, Astaldi-Ricotti GC. Antibodies from patients with rheumatoid arthritis and systemic lupus erythematosus recognize different epitopes of a single heterogeneous nuclear RNP core protein. Possible role of cross-reacting antikeratin antibodies. Arthritis Rheum. 1990 Feb;33(2):180–186. [PubMed]
  • Cartegni L, Maconi M, Morandi E, Cobianchi F, Riva S, Biamonti G. hnRNP A1 selectively interacts through its Gly-rich domain with different RNA-binding proteins. J Mol Biol. 1996 Jun 14;259(3):337–348. [PubMed]
  • Garrett DS, Lodi PJ, Shamoo Y, Williams KR, Clore GM, Gronenborn AM. Determination of the secondary structure and folding topology of an RNA binding domain of mammalian hnRNP A1 protein using three-dimensional heteronuclear magnetic resonance spectroscopy. Biochemistry. 1994 Mar 15;33(10):2852–2858. [PubMed]
  • Burd CG, Dreyfuss G. Conserved structures and diversity of functions of RNA-binding proteins. Science. 1994 Jul 29;265(5172):615–621. [PubMed]
  • Görlach M, Wittekind M, Beckman RA, Mueller L, Dreyfuss G. Interaction of the RNA-binding domain of the hnRNP C proteins with RNA. EMBO J. 1992 Sep;11(9):3289–3295. [PMC free article] [PubMed]
  • Birney E, Kumar S, Krainer AR. Analysis of the RNA-recognition motif and RS and RGG domains: conservation in metazoan pre-mRNA splicing factors. Nucleic Acids Res. 1993 Dec 25;21(25):5803–5816. [PMC free article] [PubMed]
  • James JA, Harley JB. Human lupus anti-spliceosome A protein autoantibodies bind contiguous surface structures and segregate into two sequential epitope binding patterns. J Immunol. 1996 May 15;156(10):4018–4026. [PubMed]
  • Fatenejad S, Mamula MJ, Craft J. Role of intermolecular/intrastructural B- and T-cell determinants in the diversification of autoantibodies to ribonucleoprotein particles. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12010–12014. [PMC free article] [PubMed]
  • Mamula MJ, Fatenejad S, Craft J. B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J Immunol. 1994 Feb 1;152(3):1453–1461. [PubMed]
  • James JA, Gross T, Scofield RH, Harley JB. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J Exp Med. 1995 Feb 1;181(2):453–461. [PMC free article] [PubMed]
  • van Venrooij WJ, van Gelder CW. B cell epitopes on nuclear autoantigens. What can they tell us? Arthritis Rheum. 1994 May;37(5):608–616. [PubMed]
  • Tan EM. Autoantibodies in pathology and cell biology. Cell. 1991 Nov 29;67(5):841–842. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...